Clinical trial
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young…
NCT00292071 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00292071 |
|---|---|
| Title | Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042) |
| Official title | A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 24 Months With New Onset Fever and Neutropenia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fungal Infection |
| Intervention type | Drug |
| Interventions | caspofungin acetate |
| Enrollment | 16 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Feb 15, 2006 |
| Last update posted | Feb 23, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: